- Home
- REAX vs SAVA Comparison
REAX vs SAVA Comparison
Compare REAX & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAX
- SAVA
- Stock Information
- Founded
- REAX 2018
- SAVA 1998
- Country
- REAX United States
- SAVA United States
- Employees
- REAX N/A
- SAVA N/A
- Industry
- REAX
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- REAX
- SAVA Health Care
- Exchange
- REAX Nasdaq
- SAVA Nasdaq
- Market Cap
- REAX 1.1B
- SAVA 1.3B
- IPO Year
- REAX N/A
- SAVA N/A
- Fundamental
- Price
- REAX $4.95
- SAVA $26.91
- Analyst Decision
- REAX Strong Buy
- SAVA Strong Buy
- Analyst Count
- REAX 2
- SAVA 3
- Target Price
- REAX $5.25
- SAVA $111.50
- AVG Volume (30 Days)
- REAX 774.1K
- SAVA 1.3M
- Earning Date
- REAX 11-07-2024
- SAVA 11-07-2024
- Dividend Yield
- REAX N/A
- SAVA N/A
- EPS Growth
- REAX N/A
- SAVA N/A
- EPS
- REAX N/A
- SAVA N/A
- Revenue
- REAX $1,095,350,000.00
- SAVA N/A
- Revenue This Year
- REAX $77.75
- SAVA N/A
- Revenue Next Year
- REAX $27.76
- SAVA N/A
- P/E Ratio
- REAX N/A
- SAVA N/A
- Revenue Growth
- REAX 81.37
- SAVA N/A
- 52 Week Low
- REAX $1.28
- SAVA $8.79
- 52 Week High
- REAX $6.75
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- REAX 40.26
- SAVA 51.05
- Support Level
- REAX $5.25
- SAVA $25.00
- Resistance Level
- REAX $6.61
- SAVA $28.18
- Average True Range (ATR)
- REAX 0.38
- SAVA 1.81
- MACD
- REAX -0.05
- SAVA 0.07
- Stochastic Oscillator
- REAX 1.19
- SAVA 62.39
About REAX The Real Brokerage Inc.
The Real Brokerage Inc is a technology-powered real estate brokerage firm. It has developed, integrated, and adopted various mobile and desktop-focused technologies to create a comprehensive offering to its agents and to assist Real with its brokerage operations. The group delivers a cloud-based platform to improve efficiencies and empower real estate agents to provide a seamless end-to-end experience for homebuyers and sellers. The company generates its maximum revenue from the United States.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.